Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. (Q45976336)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

main subject

California

0 references

phase I clinical trial

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

4

Heinz Josef Lenz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Primo N Lara

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Mariana Koczywas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Angela M Davies

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Derick H M Lau

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Paul H Gumerlock

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Jeff Longmate

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

James H Doroshow

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

David Schenkein

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Oscar Kashala

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

David R Gandara

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thoracic Oncology

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

126-134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

The proteasome: a suitable antineoplastic target

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Proteasome inhibitors: from research tools to drug candidates

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

The ubiquitin-proteasome pathway and proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

The proteasome, a novel protease regulated by multiple mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Proteasome inhibition: a new strategy in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Development of the proteasome inhibitor Velcade (Bortezomib).

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

An information-intensive approach to the molecular pharmacology of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Development of the proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931527-6

7 January 2021

10.1016/S1556-0864(15)31527-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409841%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference